Mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Corn (maize) became a staple food in the southeast United States and in parts of Europe. A disease that was characterized by dermatitis of sunlight-exposed skin was described in Spain in 1735 by Gaspar Casal. He attributed the cause to poor diet. In northern Italy it was named "pellagra" from the Lombard language (agra = holly-like or serum-like; pell = skin). In time, the disease was more closely linked specifically to corn. In the US, Joseph Goldberger was assigned to study pellagra by the Surgeon General of the United States. His studies confirmed a corn-based diet as the culprit, but he did not identify the root cause. Nicotinic acid was extracted from liver by biochemist Conrad Elvehjem in 1937. He later identified the active ingredient, referring to it as "pellagra-preventing factor" and the "anti-blacktongue factor." It was also referred to as "vitamin PP", "vitamin P-P" and "PP-factor", all derived from the term "pellagra-preventive factor". In the late 1930s, studies by Tom Douglas Spies, Marion Blankenhorn, and Clark Cooper confirmed that nicotinic acid cured pellagra in humans. The prevalence of the disease was greatly reduced as a result. Nicotinic acid was initially synthesized by oxidizing nicotine with potassium chromate and sulfuric acid. Hence, in 1942, when flour enrichment with nicotinic acid began, a headline in the popular press said "Tobacco in Your Bread." In response, the Council on Foods and Nutrition of the American Medical Association approved of the Food and Nutrition Board's new names niacin and niacin amide for use primarily by non-scientists.
== See also == Bibliography of veganism and vegetarianism European Vegetarian Union International Vegetarian Union List of vegetarians Plant-based diet ProVeg International Vegetarian and vegan symbolism Vegetarian cuisine Vegetarian Diet Pyramid Vegetarian nutrition Women and vegetarianism and veganism advocacy
==== South American plate ==== Trindade/Martin Vaz hotspot (41) 20°30′S 28°48′W, w= 1 az= 264° ±5° Fernando hotspot (9) 3°48′S 32°24′W, w= 1 az= 266° ±7° Possibly related to the Central Atlantic Magmatic Province (c. 200 Ma) Ascension hotspot (55) 7°54′S 14°18′W
=== Tonus Therapeutics === After completing his formal education, Sachs taught organic chemistry at Chaminade College School followed by a position as a staff fellow at the National Institutes of Health. In 1978, he accepted an assistant professor position in the University at Buffalo's Department of Pharmacology. In this role, Sachs discovered mechanosensitive ion channels which are sensors for systems including the senses of hearing, touch, and balance. As a result of his discovery, he also created the only drug to inhibit these channels. Sachs believed that spider venom could contain molecular compounds that could block the ion channels. After discovering the possibility of a drug, he was contacted by several large pharmaceutical companies but none offered to adopt the drug. He eventually co-launched Rose Pharmaceuticals in 2009, which was named after Sachs’ pet tarantula and grandmother, with a stockbroker named Harvey whose grandson had had Duchenne muscular dystrophy. The following year, the Food and Drug Administration designated the firm’s peptide, called GsMTx4, as an orphan drug for Duchenne muscular dystrophy. In 2012, Sachs and Harvey opened their first-ever headquarters in UB’s New York State Center of Excellence in Bioinformatics and Life Sciences and re-named the company Tonus Therapeutics. Within two years, the company sold the rights to their drug to Akashi Therapeutics. He also began studying AT-300’s effectiveness in dystrophic mice.
Sources: en.wikipedia.org
=== Critical response === The first season received critical acclaim. The review aggregator Rotten Tomatoes reported an 100% approval rating based on 74 critics’ reviews, with an average rating of 8.3/10. The website's critics consensus states, "A prickling debut that pulls few punches, Hacks deftly balances its sharp critiques of the comedy world with more intimate moments, all the while giving the incomparable Jean Smart a role worthy of her talents – and an excellent partner in Hannah Einbinder." Metacritic calculated a weighted average score of 82 out of 100 based on 24 critics.
== Academic achievements and research == Holick is an author of more than 400 publications about the biochemistry, physiology, metabolism and photobiology of vitamin D and the pathophysiology of vitamin D deficiency. He has been quoted and his scientific work has been referenced in The New York Times, Forbes, Newsweek, Men's Health, Scientific American and Time. He wrote several books about the importance of vitamin D and its beneficial health effects to the broad public, and discussed the benefits of sensible and the risks of excessive sun exposure. As a graduate student, he identified the major circulating form of vitamin D, 25-hydroxyvitamin D3, which is the vitamin D metabolite that is measured by physicians worldwide to determine a patient's vitamin D status. He also identified the active form of vitamin D, 1,25-dihydroxyvitamin D3, as well as other metabolites including 24,25-dihydroxyvitamin D3, 1,24,25-trihydroxyvitamin D3 and 25,26-dihydroxyvitamin D3. As a fellow, he participated in the first chemical synthesis of 1,25-dihydroxyvitamin D3 and 1α-hydroxyvitamin D3 to treat renal osteodystrophy, hypoparathyroidism, vitamin D dependent rickets type I, and osteoporosis. Furthermore, he elucidated the pathophysiology of hereditary vitamin D-dependent rickets which involves defective vitamin D metabolism, and the pathophysiological mechanisms of X-linked hypophosphatemic rickets.
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, EDAC or EDCI) is a water-soluble carbodiimide usually handled as the hydrochloride, which is a white solid. It is typically employed in the 4.0-6.0 pH range. It is generally used as a carboxyl activating agent for the coupling of primary amines to yield amide bonds. While other carbodiimides like dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIC) are also employed for this purpose, EDC has the advantage that the urea byproduct formed (often challenging to remove in the case of DCC or DIC) can be washed away from the amide product using dilute acid. Additionally, EDC can also be used to activate phosphate groups in order to form phosphomonoesters and phosphodiesters. Common uses for this carbodiimide include peptide synthesis, protein crosslinking to nucleic acids, but also in the preparation of immunoconjugates. EDC is often used in combination with N-hydroxysuccinimide (NHS) for the immobilisation of large biomolecules. Recent work has also used EDC to assess the structure state of uracil nucleobases in RNA.
The colonies of Queensland and South Australia along with the Northern Territory, where three of the four states of colonial Australia which still had large, yet unknown numbers of Aboriginal people living on Country in regional, remote and very remote locations. From time to time, this made in necessary for laws to be created so Australian’s living within the colony understood their responsibilities to society, and the law was working to ensure protection from potential exploitation, perceived or otherwise. By 1897 the passage of law in all three of the above locations had restricted the sale, exchange or trade of opium with any Aboriginal person without exception, this broad application was required to ensure the law was enforceable. Hardening of Canadian attitudes toward Chinese opium users and fear of a spread of the drug into the white population led to the effective criminalization of opium for nonmedical use in Canada between 1908 and the mid-1920s. In 1909, the International Opium Commission was founded, and by 1914, 34 nations had agreed that the production and importation of opium should be diminished. In 1924, 62 nations participated in a meeting of the commission. Subsequently, this role passed to the League of Nations, and all signatory nations agreed to prohibit the import, sale, distribution, export, and use of all narcotic drugs, except for medical and scientific purposes.
4 August – Tom Sawyer, Baron Sawyer, 82, British trade unionist and politician, member of the House of Lords (since 1998). (death announced on this date) 12 August – Hefin David, 47, Welsh politician, Member of the Senedd (2016–2025). Sir George Reid, 86, Scottish politician, presiding officer of the Scottish Parliament (2003–2007), kidney cancer. 20 August – Dame Annette Brooke, 78, British politician, MP (2001–2015). 21 August – Swraj Paul, Baron Paul, 94, Indian-born British industrialist and politician, member of the House of Lords (since 1996). 22 August – Martin Smyth, 94, Northern Irish politician, MLA (1982–1986) and MP (1982–2005). (death announced on this date) 26 August – David Warburton, 59, British politician, MP (2015–2023). 30 August – Tim Boswell, Baron Boswell of Aynho, 82, British politician, MP (1987–2010) and member of the House of Lords (2010–2025). 10 September – Alan Howarth, Baron Howarth of Newport, 81, British politician, MP (1983–2005) and member of the House of Lords (since 2005). 17 September – Barry Seal, 87, British politician, MEP (1979–1999), acute myeloid leukaemia. 18 September – Charles Guthrie, Baron Guthrie of Craigiebank, 86, British field marshal, assistant chief (1987–1989) and chief (1994–1997) of the general staff, chief of the defence staff (1997–2001), ruptured cerebral aneurysm. 23 September – Iain Coleman, 67, British politician, MP (1997–2005). (death announced on this date) 26 September – Menzies Campbell, 84, British politician, MP (1987–2015).
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.